levofloxacin has been researched along with clavulanic acid in 22 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (clavulanic acid) | Trials (clavulanic acid) | Recent Studies (post-2010) (clavulanic acid) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 1,801 | 212 | 424 |
| Protein | Taxonomy | levofloxacin (IC50) | clavulanic acid (IC50) |
|---|---|---|---|
| Beta-lactamase | Klebsiella pneumoniae | 1.72 | |
| Beta-lactamase | Escherichia coli | 0.07 | |
| Beta-lactamase | Citrobacter gillenii | 0.009 | |
| Beta-lactamase | Shouchella clausii | 0.085 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Staphylococcus aureus | 0.08 | |
| Beta-lactamase | Escherichia coli K-12 | 0.015 | |
| Beta-lactamase SHV-1 | Escherichia coli | 0.028 | |
| Beta-lactamase SHV-1 | Klebsiella pneumoniae | 0.17 | |
| Beta-lactamase OXA-1 | Escherichia coli | 3.2 | |
| Cytochrome P450 2B6 | Homo sapiens (human) | 0.17 | |
| Beta-lactamase | Pseudomonas aeruginosa PAO1 | 0.8 | |
| Beta-lactamase TEM | Escherichia coli | 0.0933 | |
| Beta-lactamase | Salmonella enterica subsp. enterica serovar Westhampton | 0.01 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Klebsiella pneumoniae | 0.02 | |
| Class D beta-lactamase | Brachyspira pilosicoli | 2 | |
| Beta-lactamase | Pseudomonas luteola | 0.036 | |
| Beta-lactamase | Escherichia coli | 8.6 | |
| Beta-lactamase | Escherichia coli | 0.009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 5 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Léophonte, P; Veyssier, P | 1 |
| Kanayama, A; Kobayashi, I; Mochida, O; Naito, S; Saika, T; Tanaka, M; Tunoe, H | 1 |
| Díaz de Tuesta Chow-Quan, AM; Dimas Nuñez, JF; Geijo Martínez, MP; Gómez Criado, C; Herranz, CR; Saiz García, F | 1 |
| Berry, V; Hoover, J; Singley, C; Woodnutt, G | 1 |
| Appelbaum, PC; Clark, CL; Ednie, LM; Kosowska-Shick, K | 1 |
| Aguilar, L; Alou, L; Echeverría, O; Giménez, MJ; González, N; Martín, JE; Prieto, J; Sevillano, D; Torrico, M; Valdés, L | 1 |
| Aguilar, L; Alió, JJ; Alou, L; Cafini, F; Giménez, MJ; González, N; Manso, F; Prieto, J; Sevillano, D; Torrico, M | 1 |
| Chen, MC; Hu, CT; Lei, WY; Lin, JS; Wu, DC; Yi, CH | 1 |
| Aregbesola, SB; Braimah, RO; Ndukwe, KC; Owotade, JF | 1 |
| Gökçe, A; Gönül, M; Yuksek, T | 1 |
| Minami, K; Nishihara, M; Oda, K; Suzuki, K; Uchiyama, K; Ukimura, A; Yamada, T | 1 |
| Heiland, M; Menzel, P; Nahles, S; Neckel, N; Preissner, S; Schwarzer, R; Wagendorf, O | 1 |
| Hu, S; Lou, Z; Shen, Y; Tu, M | 1 |
| Chen, J; Liu, W; Zhao, F | 1 |
1 review(s) available for levofloxacin and clavulanic acid
| Article | Year |
|---|---|
Bacteriological Studies of Venomous Snakebite Wounds in Hangzhou, Southeast China.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; Bacteria; Cefazolin; Cefoxitin; Ciprofloxacin; Clavulanic Acid; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Snake Bites; Sulbactam; Venoms | 2022 |
4 trial(s) available for levofloxacin and clavulanic acid
| Article | Year |
|---|---|
[Levofloxacin in the treatment of community-acquired pneumococcal pneumonia].
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Clavulanic Acid; Community-Acquired Infections; Drug Therapy, Combination; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pneumonia, Pneumococcal | 1999 |
[Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Clavulanic Acid; Community-Acquired Infections; Drug Therapy, Combination; Female; Hospitalization; Humans; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2002 |
Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection.
Topics: Amoxicillin; Clavulanic Acid; Drug Combinations; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Rabeprazole | 2014 |
Impact of oral antibiotics on health-related quality of life after mandibular third molar surgery: An observational study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; beta-Lactamase Inhibitors; Clavulanic Acid; Female; Humans; Levofloxacin; Male; Molar, Third; Oral Health; Postoperative Care; Preoperative Care; Quality of Life; Surgical Wound Infection; Surveys and Questionnaires; Tooth Extraction; Tooth, Impacted; Treatment Outcome; Young Adult | 2017 |
17 other study(ies) available for levofloxacin and clavulanic acid
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Gonorrhea; Humans; Levofloxacin; Naphthyridines; Neisseria gonorrhoeae; Norfloxacin; Ofloxacin | 2000 |
Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Animals; Azithromycin; Clavulanic Acid; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Rats; Rats, Sprague-Dawley; Streptococcus pneumoniae | 2005 |
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Imipenem; Ketolides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2007 |
Levofloxacin vs. azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Clavulanic Acid; Computer Simulation; Drug Resistance, Bacterial; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 2007 |
In vitro killing activity of crevicular concentrations of tinidazole plus common oral antibiotics against high-density mixed inocula of periodontal pathogens in strict anaerobic conditions.
Topics: Amoxicillin; Anti-Bacterial Agents; Bacteria, Anaerobic; Clavulanic Acid; Clindamycin; Drug Synergism; Drug Therapy, Combination; Gingival Crevicular Fluid; Humans; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Ofloxacin; Periodontal Diseases; Tinidazole | 2010 |
Drug-Induced Histiocytoid Sweet Syndrome: Two Cases With Levofloxacin and Amoxicillin-Clavulanate.
Topics: Amoxicillin; Clavulanic Acid; Histiocytes; Humans; Levofloxacin; Sweet Syndrome | 2022 |
Probability of target attainment of oral antimicrobials for Escherichia coli and Klebsiella pneumoniae based on Monte Carlo simulations.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cephalexin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Probability | 2022 |
Sonication versus the conventional method for evaluation of the dental microbiome: a prospective pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bacteria; Clavulanic Acid; Dental Caries; Humans; Levofloxacin; Microbiota; Pilot Projects; Prospective Studies; Sonication | 2022 |
Analysis of drug resistance genes of integrons in clinical isolates of Escherichia coli from elderly bloodstream infections.
Topics: Aged; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cefoxitin; Clavulanic Acid; Drug Resistance; Escherichia coli; Escherichia coli Infections; Gentamicins; Humans; Integrons; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Minocycline; Sepsis; Ticarcillin; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |